NasdaqCM - Delayed Quote USD

Curis, Inc. (CRIS)

Compare
5.05 +0.04 (+0.80%)
At close: 4:00 PM EDT
Loading Chart for CRIS
DELL
  • Previous Close 5.01
  • Open 5.01
  • Bid --
  • Ask --
  • Day's Range 5.00 - 5.12
  • 52 Week Range 3.80 - 17.49
  • Volume 24,240
  • Avg. Volume 47,037
  • Market Cap (intraday) 30.194M
  • Beta (5Y Monthly) 3.32
  • PE Ratio (TTM) --
  • EPS (TTM) -8.17
  • Earnings Date Oct 31, 2024 - Nov 4, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 22.50

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.

www.curis.com

49

Full Time Employees

December 31

Fiscal Year Ends

Recent News: CRIS

View More

Performance Overview: CRIS

Trailing total returns as of 10/9/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

CRIS
60.39%
S&P 500
21.43%

1-Year Return

CRIS
1.17%
S&P 500
34.43%

3-Year Return

CRIS
32.93%
S&P 500
31.90%

5-Year Return

CRIS
119.57%
S&P 500
100.20%

Compare To: CRIS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: CRIS

View More

Valuation Measures

Annual
As of 7/12/2024
  • Market Cap

    30.01M

  • Enterprise Value

    5.21M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.85

  • Price/Book (mrq)

    4.32

  • Enterprise Value/Revenue

    0.51

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -45.97%

  • Return on Equity (ttm)

    -372.67%

  • Revenue (ttm)

    10.16M

  • Net Income Avi to Common (ttm)

    -47.57M

  • Diluted EPS (ttm)

    -8.17

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    28.36M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -25.84M

Research Analysis: CRIS

View More

Earnings Per Share

Consensus EPS
 

Revenue vs. Earnings

Revenue 2.55M
Earnings -11.8M
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Analyst Price Targets

18.00
22.50 Average
5.05 Current
26.00 High
 

Company Insights: CRIS

People Also Watch